|Reference : Prostaglandines, secretion d'insuline et diabete sucre.|
|Scientific journals : Article|
|Human health sciences : Endocrinology, metabolism & nutrition|
|Prostaglandines, secretion d'insuline et diabete sucre.|
|[fr] Prostaglandins, insulin secretion and diabetes mellitus|
|Giugliano, D. [> > > >]|
|Torella, R. [> > > >]|
|Scheen, André [Université de Liège - ULg > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale >]|
|Lefebvre, Pierre [Centre Hospitalier Universitaire de Liège - CHU > > Diabétologie,nutrition, maladies métaboliques >]|
|D'Onofrio, F. [> > > >]|
|Diabète & Métabolisme|
|Yes (verified by ORBi)|
|[en] Animals ; Diabetes Mellitus/physiopathology ; Humans ; Islets of Langerhans/drug effects/secretion ; Prostaglandins/pharmacology/physiology|
|[en] The islets of Langerhans have the enzymatic equipment permitting the synthesis of the metabolites of arachidonic acid: cyclo-oxygenase and lipo-oxygenase. Numerous studies have shown that cyclo-oxygenase derivatives, mainly PGE2, reduce the insulin response to glucose whereas lipo-oxygenase derivatives, mainly 15-HPETE, stimulate insulin secretion. So, for instance, drugs that increase prostaglandins synthesis as colchicine or furosemide inhibit insulin secretion while non steroid anti-inflammator drugs, mainly salicylates, which inhibit cyclo-oxygenase, enhance the insulin response to various stimuli. In type-2 (non insulin-dependent) diabetes, an increased sensitivity to endogenous prostaglandins has been proposed as a possible cause for the insulin secretion defect which characterizes this disease. Play in favor of this hypothesis the fact that the administration of PGE inhibits the insulin response to arginine in type-2 diabetics but not in normal subject and the fact that the administration of salicylates could improve the insulin response to glucose in some of these patients.|
There is no file associated with this reference.
All documents in ORBi are protected by a user license.